Tristan Richard Gordon Sillars
Directeur des opérations chez Arquer Diagnostics Ltd.
Profil
Tristan Richard Gordon Sillars is currently the Chief Operating Officer & Director at Arquer Diagnostics Ltd.
He previously worked as an Associate at KPMG Transaction Services Group.
Postes actifs de Tristan Richard Gordon Sillars
Sociétés | Poste | Début |
---|---|---|
Arquer Diagnostics Ltd.
Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Directeur des opérations | - |
Anciens postes connus de Tristan Richard Gordon Sillars
Sociétés | Poste | Fin |
---|---|---|
KPMG Transaction Services Group | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Arquer Diagnostics Ltd.
Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
KPMG Transaction Services Group |